MM-141

DRUG3 trials

Sponsors

Merrimack Pharmaceuticals

Conditions

Colorectal CancerHepatocellular CarcinomaNon-small Cell Lung CancerPancreatic CancerSquamous Cell Carcinoma of the Head and Neck

Phase 1

A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors

CompletedNCT01733004

Merrimack PharmaceuticalsHepatocellular Carcinoma

Start: 2012-11-30Updated: 2016-08-04

Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib

TerminatedNCT02538627

Merrimack PharmaceuticalsColorectal Cancer, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck

Start: 2015-08-31End: 2016-10-05Updated: 2017-09-05

Phase 2

A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer

CompletedNCT02399137

Merrimack PharmaceuticalsPancreatic Cancer

Start: 2015-05-31End: 2018-08-31Updated: 2018-09-18

Related Papers

Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE).

2020-01-0141 citations

A phase 1 biomarker-directed multi-arm study evaluating the co-administration of MM-151 with MM-121, MM-141, or trametinib in EGFR-driven cancers.

Journal of Clinical Oncology2016-05-201 citations

A multicenter phase II study of istiratumab (MM-141) plus nab-paclitaxel (A) and gemcitabine (G) in metastatic pancreatic cancer (MPC).

Journal of Clinical Oncology2016-02-0110 citations

First-in-human study of MM-141: A novel tetravalent monoclonal antibody targeting IGF-1R and ErbB3.

Journal of Clinical Oncology2015-01-2012 citations

First-in-human study of MM-141: A novel tetravalent monoclonal antibody targeting IGF-1R and ErbB3.

Journal of Clinical Oncology2014-05-205 citations